{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:47:37Z","timestamp":1780505257888,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY031097"],"award-info":[{"award-number":["EY031097"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41434-021-00233-1","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T16:18:42Z","timestamp":1612455522000},"page":"740-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina"],"prefix":"10.1038","volume":"28","author":[{"given":"Kun","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-8229","authenticated-orcid":false,"given":"Peter A.","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"233_CR1","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber\u2019s Congenital Amaurosis. N Eng J Med. 2008;358:2240\u20138.","journal-title":"N Eng J Med"},{"key":"233_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","volume":"24","author":"K Xue","year":"2018","unstructured":"Xue K, K JJ, Barnard aR, Rudenko A, Salvetti AP, Patricio MI, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24:1507\u201312.","journal-title":"Nat Med"},{"key":"233_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/hum.2006.17.167","volume":"17","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17:167\u201376.","journal-title":"Hum Gene Ther"},{"key":"233_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/hum.2016.117","volume":"28","author":"PA Campochiaro","year":"2016","unstructured":"Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, et al. Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study. Hum Gene Ther. 2016;28:99\u2013111.","journal-title":"Hum Gene Ther"},{"key":"233_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","volume":"389","author":"JS Heier","year":"2017","unstructured":"Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. The Lancet. 2017;389:50\u201361.","journal-title":"The Lancet"},{"key":"233_CR6","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","volume":"372","author":"SG Jacobson","year":"2015","unstructured":"Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372:1920\u20136.","journal-title":"N Engl J Med"},{"key":"233_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661\u201372.","journal-title":"Lancet"},{"key":"233_CR8","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1172\/JCI129085","volume":"130","author":"K Ding","year":"2019","unstructured":"Ding K, Shen J, Hafiz Z, Hackett SF, Lima e Silva R, Khan M, et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J Clin Invest. 2019;130:4901\u201311.","journal-title":"J Clin Invest"},{"key":"233_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3002103","volume":"3","author":"LH Vandenberghe","year":"2011","unstructured":"Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Trans Med. 2011;3:1\u20139.","journal-title":"Sci Trans Med"},{"key":"233_CR10","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1073\/pnas.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong L, Li B, Mah CS, Govindasamy L, Aqbandle-McKenna M, Cooper M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA. 2008;105:7827\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"233_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/mt.2010.234","volume":"19","author":"H Petrs-Silva","year":"2011","unstructured":"Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Seok-Hong M, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. 2011;19:293\u2013301.","journal-title":"Mol Ther"},{"key":"233_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jgm.516","volume":"6","author":"AR Brooks","year":"2004","unstructured":"Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med. 2004;6:395\u2013404.","journal-title":"J Gene Med"},{"key":"233_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/scd.2006.0057","volume":"16","author":"X Xia","year":"2007","unstructured":"Xia X, Zhang Y, Zieth CR, Zhang SC. Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev. 2007;16:167\u201376.","journal-title":"Stem Cells Dev"},{"key":"233_CR14","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1167\/iovs.07-0257","volume":"48","author":"SC Khani","year":"2007","unstructured":"Khani SC, Pawlyk BS, Bulgakov OV, Kasperek E, Young JE, Adamian M, et al. AAV-mediated expression targeting rod and cone photreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci. 2007;48:3954\u201361.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"233_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1128\/JVI.75.4.1824-1833.2001","volume":"75","author":"A-M Douar","year":"2001","unstructured":"Douar A-M, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol. 2001;75:1824\u20133.","journal-title":"J Virol"},{"key":"233_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ymthe.2004.10.020","volume":"11","author":"K Jennings","year":"2005","unstructured":"Jennings K, Miyamae T, Traister R, Marinov A, Katakura S, Sowders D, et al. Proteasome inhibition enhances AAV-mediated trangene expression in human synoviocytes in vitro and in vivo. Mol Ther. 2005;11:600\u20137.","journal-title":"Mol Ther"},{"key":"233_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/mt.2010.170","volume":"18","author":"PE Monahan","year":"2010","unstructured":"Monahan PE, Lothrop CD, Sun J, Hirsch ML, Kafri T, Kantor B, et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther. 2010;18:1907\u201316.","journal-title":"Mol Ther"},{"key":"233_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chom.2011.10.014","volume":"10","author":"M Nonnenmacher","year":"2011","unstructured":"Nonnenmacher M, Weber T. Adeno-associated virus 2 infection requires endocytosis through the CLIC\/GEEC pathway. Cell Host Microbe. 2011;10:563\u201376.","journal-title":"Cell Host Microbe"},{"key":"233_CR19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ymthe.2005.11.007","volume":"13","author":"G Di Pasquale","year":"2005","unstructured":"Di Pasquale G, Chiorini JA. AAV transcytosis through barrier epithelia and endothelium. Mol Ther. 2005;13:506\u201316.","journal-title":"Mol Ther"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00233-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:06:41Z","timestamp":1639613201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00233-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00233-1","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors have a conflict of interest directly related to the content of the manuscript, but PAC has unrelated financial disclosures: AERPIO PHARMACEUTICALS: Advisory Board, Honoraria to JHU, Investigator, Grant; ALLEGRO: Advisory Board, Equity; APPLIED GENETIC TECHNOLOGIES CORPORATION: Advisory Board, Honoraria;ASCLEPIX THERAPEUTICS: Consultant, Honoraria; BAUCSH and LOMB: Consultant, Honoraria; CUREVAC: Consultant, Honoraria; EXONATE LTD: Advisory Board, Honoraria GENENTECH\/ROCHE INC: Advisory Board, Honoraria to JHU, Investigator, Grants; SANOFI GENZYME: Investigator, Grant; GRAYBUG VISION: Consultant, Honoraria, Co-Founder, Equity, Grant; MERCK & CO, INC: Advisory Board, Honoraria; OXFORD BIOMEDICA: Investigator, Grant; PERFUSE; REGENERON PHARMACEUTICALS, INC: Investigator, Grant; REGENXBIO, INC: Investigator, Grant; WAVE LIFE SCIENCES: Consultant, Honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}